Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8596055 | 1.00 | CA2 (0.58) | CA2KDM4ECA5ACA5BCYP3A4 | |
| SCHEMBL105 | 1.00 | — | — | |
| SCHEMBL246838 | 1.00 | CA2 (0.58) | CA2KDM4ECA5ACA5BCYP3A4 | |
| SCHEMBL128169 | 1.00 | — | — | |
| SCHEMBL15109974 | 1.00 | — | — | |
| SCHEMBL10855525 | 0.94 | — | — | |
| SCHEMBL20570028 | 0.94 | — | — | |
| SCHEMBL3365970 | 0.94 | — | — | |
| SCHEMBL20570964 | 0.94 | — | — | |
| SCHEMBL21641627 | 0.94 | CA2 (0.54) | CA2KDM4ECA5ACA5BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4504736-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | claimed |
| EP-4444720-A1 | RABEXIMOD COMPOUNDS | Cyxone AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023196900-A9 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| US-20230321009-A1 | USE OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING BREAST CANCER | SHENZHEN CHINA RESOURCES JIUCHUANG MEDICAL AND PHARMACEUTICAL CO., LTD (CN) | 2023-10-12 | — | — | US | claimed |
| WO-2023196900-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| EP-3801480-B1 | SAFINAMIDE FOR TREATING MYOTONIA | ZAMBON SPA (IT) | 2023-07-05 | — | — | EP | claimed |
| CN-107915657-A | A kind of preparation method for the medicine methanesulfonic acid safinamide for treating Parkinson's | 孙婷婷 | 2018-04-17 | — | — | CN | claimed |
| US-20120046471-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | SALTIGO GMBH (DE) | 2012-02-23 | — | — | US | claimed |
| US-8030520-B2 | Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide | SALTIGO GMBH (DE) | 2011-10-04 | — | — | US | claimed |
| EP-2107047-B1 | Method for producing organic compounds by means of a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halogenide | SALTIGO GMBH (DE) | 2011-09-28 | — | — | EP | claimed |
| US-20110220844-A1 | SULFONATE MODIFIED NANOCRYSTALS | Life Technologies Corporation | 2011-09-15 | — | — | US | claimed |
| US-8003617-B2 | e.g. 1-(3',4'-ethylenedioxy)phenyl-2-nonanoylamino-3-pyrrolidino-1-propanol; glucosylceramide synthase inhibitor; inhibits glycosphingolipid synthesis; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, Gaucher's disease | GENZYME CORPORATION (US) | 2011-08-23 | — | — | US | claimed |
| EP-2342161-A2 | SULFONATE MODIFIED NANOCRYSTALS | Life Technologies Corporation (US) | 2011-07-13 | — | — | EP | claimed |
| US-7935852-B2 | Fluoridation method | GE HEALTHCARE LIMITED (GB) | 2011-05-03 | — | — | US | claimed |
| US-20110053987-A1 | PYRIDINIUM AND THIAZOLIUM CONJUGATES INCLUDING POLYETHYLENE GLYCOLS AND METHODS OF USING THE SAME | MYCOSOL, INC. | 2011-03-03 | — | — | US | claimed |
| US-20110034530-A1 | PROCESS FOR THE PREPARATION OF FIPRONIL AND ANALOGUES THEREOF | VETOQUINOL (FR) | 2011-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034530-A1 | PROCESS FOR THE PREPARATION OF FIPRONIL AND ANALOGUES THEREOF | NOX5, CYP3A5, PPOX | CA2 446/4885KDM4E 863/4885CA5A 7/4885 |
| US-20110053987-A1 | PYRIDINIUM AND THIAZOLIUM CONJUGATES INCLUDING POLYETHYLENE GLYCOLS AND METHODS OF USING THE SAME | PLPBP, PTPMT1, PNPO | CA2 4174/4885KDM4E 2342/4885CA5A 1325/4885 |
| US-20120046471-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | TIMCC, ZFX, TSNAX | CA2 2308/4885KDM4E 208/4885CA5A 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.